EP0098392A2 - Membran und Verfahren zu ihrer Herstellung - Google Patents
Membran und Verfahren zu ihrer Herstellung Download PDFInfo
- Publication number
- EP0098392A2 EP0098392A2 EP83105534A EP83105534A EP0098392A2 EP 0098392 A2 EP0098392 A2 EP 0098392A2 EP 83105534 A EP83105534 A EP 83105534A EP 83105534 A EP83105534 A EP 83105534A EP 0098392 A2 EP0098392 A2 EP 0098392A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- membrane
- polymer
- designating
- polymer solution
- polyamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 67
- 238000001914 filtration Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 21
- 229920000642 polymer Polymers 0.000 claims abstract description 49
- 239000012510 hollow fiber Substances 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 15
- 239000004952 Polyamide Substances 0.000 claims abstract description 14
- 229920002647 polyamide Polymers 0.000 claims abstract description 14
- 230000035699 permeability Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229920002492 poly(sulfone) Polymers 0.000 claims description 4
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims 2
- 229920000570 polyether Polymers 0.000 claims 2
- 125000001174 sulfone group Chemical group 0.000 claims 2
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 19
- 238000002615 hemofiltration Methods 0.000 abstract description 11
- 239000003978 infusion fluid Substances 0.000 abstract description 8
- 102000009027 Albumins Human genes 0.000 abstract description 3
- 108010088751 Albumins Proteins 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000002596 correlated effect Effects 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- -1 polyethersulphone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/24—Formation of filaments, threads, or the like with a hollow structure; Spinnerette packs therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/56—Polyamides, e.g. polyester-amides
Definitions
- This invention relates to a filtration membrane which is especially, though not exclusively, adapted for use in hemofiltration.
- the invention relates to a process for producing a membrane of this type, in which a polymer solution is extruded with a center liquid to form a membrane extrudate which is then optionally washed.
- Hemofiltration membranes are well known in the art. For example, in the U.S. Patent 4 229 291 there is described a polyamide hemofiltration membrane as well as a process for producing the membrane. A similar membrane is described also in the German Patent Publication DE-AS 22 36 226. Hemofiltration membranes made of other polymers than polyamide are also known and commercially available. Examples are membranes made of cellulose nitrate (Sartorius; Daicel), polyacrylonitrile (Asahi PAN 15; Rhone-Poulenc AN 69), polysulphone (Amicon), and polyether- polycarbonate block copolymer (European Patent Application No. 801051185.5).
- a common drawback of these known membranes is their relatively low ultrafiltration rates (permeabilities to water), which require that compensating relatively large membrane surface areas are used to obtain at least a minimal required liquid flow-through when the membranes are used in for example hemofiltration. Since the minimal required liquid flow-through is even higher in the filtration of infusion solutions an accordingly larger compensating membrane surface area must therefore be used.
- a known filtration membrane according to either of U.S. Patent 4 229 291 and German Patent Publication DE-AS 22 36 226, which has an ultrafiltration rate of 10 - 20 x 10- 4 ml/sec. x cm 2 x bar and 10 - 30 x 10 -4 ml/sec.
- An object of this invention is therefore to provide a filtration membrane which is far better than the known filtration membranes as regards the ability to filtrate liquids at high rates.
- An especial object is to provide a hemofiltration membrane which in comparison to the known filtration membranes requires only a minimum of compensating surface area to be able to filtrate for example blood at the required flow-through rate.
- a further object of the invention is to provide a process for producing the above-mentioned improved membrane according to this invention.
- a filtration membrane particularly for use in hemofiltration.
- Said membrane is characterized by having.an ultrafiltration rate (permeability to water) of between 200 x 10- 4 and 500 x 10- 4 ml/sec. x cm 2 x bar (at 20°C) and by being essentially impermeable to albumin (M w 44,000).
- a process for producing said filtration membrane in the form of a hollow fiber wherein a polymer solution is extruded with a center liquid to form a membrane extrudate which is then optionally washed.
- Said process is characterized in that the polymer solution is extruded under conditions such that the volume of polymer solution to volume of center liquid ratio is within the range of from 2:1 to 4:1.
- the present membrane is an asymmetric, self- supporting membrane and may be in the form of a flat sheet, a tube or a hollow fiber.
- the hollow fiber shape is the most preferred form.
- a membrane in general, can be used for hemofiltration if it fulfils the following criteria: non-toxicity, blood compatibility, low tendency for the adsorption of proteins, sharp cut-off, high filtration rates and physical stability.
- the chemical composition of the membrane material is a major factor, because it greatly influences the membrane structure and it also determines the interaction between blood and membrane.
- suitable membrane materials which fulfil all of said criteria may be polymers which are soluble in a polar, non-protonic organic solvent.
- solvents are dimethylsulphoxide (DMSO), dimethylformamide (DMF), and dimethylacetate (DMAc).
- suitable polymers for the present membrane are polysulphone, polyethersulphone, polycarbonate, polyacrylonitrile, polyamide, and polystyrol.
- the most preferred polymer among these is polyamide.
- An example of an especially preferred polyamide according to the present invention is a polyamide having -repeating units of the following chemical formula: wherein R 1 is designating hydrogen and R 2 , R 3 and R 4 each are designating a (C 1 -C 5 )alkyl group, preferably methyl or wherein R 3 is designating hydrogen and R l , R 2 and R 4 each are designating a (C 1 -C 5 )alkyl group, preferably methyl.
- the wall thickness of the membrane may vary, but is preferably within the range of from 40 to 100 ⁇ m with an inner barrier layer of ca 0.1 ⁇ m.
- the cut-off of the membrane is about 30,000 Daltons.
- a membrane of the above-mentioned type is produced by extruding a polymer solution with a center liquid under conditions such that the volume of polymer solution to volume of center liquid ratio is within the range of from 2:1 to 4:1.
- said inner diameter to wall thickness ratio may vary within the range of from 150:75 to 280:75, preferably 220:75.
- said polymer concentration may vary within the range of from 5 to 20X.
- a polymer concentration outside this range will lead to a membrane which is either too rubbery or which is being inferior as regards the ultrafiltration characteristics.
- An especially preferred polymer concentration is 11%.
- the ultrafiltration rate of the membrane will be inferior to 100 x 10 -4 ml/cm 2 x atm. while the ultrafiltration rate is about 400 x 10 -4 ml/sec. x cm 2 x atm. at an inner diameter to wall thickness ratio of 250:75.
- the maximal ultrafiltration rates up to 500 x 10 -4 ml/sec. x cm 2 x atm.
- the high- permeable membranes in the extrusion-process is that the polymer solution after leaving the die and before reaching a first wash bath is completely exchanged by the center ' liquid from inside of the hollow fiber, i.e. the residence time in the ambient atmosphere before the hollow fiber extrudate reaches said first wash bath must involve a minimum of time and the distance between the die and the wash bath must be at least a minimal distance.
- said minimal residence time is about 2 sec. in the ambient atmosphere (at a hollow fiber production rate of 30 meters/minute) before the hollow fiber extrudate is introduced into the wash bath.
- the hollow fiber extrudate is completely formed from inside, i.e. the hollow fiber extrudate will not be effected by the wash bath. Consequently, there will be formed no outer barrier layer, which will be the case if the residence time under the given conditions is too short.
- polymers for said polymer solution may be the polymers mentioned above, and examples of suitable solvents may be DMSO, DMF, DMAc or similar polar, non-protonic organic solvents.
- Water may be used as said center liquid, preferably deionized water.
- the polymer solution viscosity is generally from 100 to 3,000 cps, preferably 300 cps, as measured at 20°C.
- the polymer solution (105 ml/h) was extruded with ion-free water as a center liquid (50 ml/h) through an annular die to form a hollow fiber extrudate having an inner diameter of 190 ⁇ m and an outer diameter of 340 ⁇ m. After passing a height of fall (1 meter) through the ambient atmosphere the hollow fiber extrudate was introduced in a fist wash bath and consecutively through following wash baths of different temperatures with different residence times, until the solvent had been completely washed out.
- Example 2 The same process conditions as in Example 1 were used.
- the dimensions of the hollow fiber varied by varying the volume rates of center liquid (88 ml/h) and polymer solution (126 ml/h).
- the inner diameter of the hollow fiber was 250 ⁇ m and the outer diameter was 400 ⁇ m.
- Example 2 The same process conditions as in Example 1 were used.
- the dimensions of the hollow fiber were varied by varying the volume rate of center liquid (64 ml/h) and polymer solution (110 mlth).
- the inner diameter of the hollow fiber was 220 ⁇ m and the outer diameter was 370 ⁇ m.
- this hollow fiber When used in a hemofilter having an effective membrane surface area of 1.16 m 2 and an effective hollow fiber length of 25 cm, this hollow fiber had a filtration performance for blood (25% Hct, 70 mg/1 total albumin, 37 0 C) of 120 ml/min.
- the blood flow rate was 350 ml/min.
- this hollow fiber When used as an infusion solution filter having a surface area of 0.1 m 2 and an effective hollow fiber length of 10 cm, this hollow fiber filtered 300 ml/min. of infusion solution at a transmembrane pressure of 200 mmHg.
- the filtered infusion solution contained 1,000 ng/1 endotoxins, no endotoxins could be detected in the filtrate. Detectable limit 0.05 ng/l. Examples of such tested endotoxins are E-Coliendotoxin and Lysate IGQ having molecular weights of between 50,000 and 1 x 10 6 Daltons.
- the present filtration membrane is particularly though not exclusively, adapted for use in hemofiltration.
- the membrane can be used in any other filtration procedures requiring high flow-through rates, such as for example filtration of infusion solutions. More in general, the membrane can be used in applications requiring that the membrane fulfils the following critera: non-toxicity, blood compatibility, low tendency for the adsorption of proteins, sharp cut-off, high filtration rates and physical stability.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Textile Engineering (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Artificial Filaments (AREA)
- Polyamides (AREA)
- External Artificial Organs (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT83105534T ATE31248T1 (de) | 1982-07-02 | 1983-06-06 | Membran und verfahren zu ihrer herstellung. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8204103 | 1982-07-02 | ||
SE8204103A SE8204103L (sv) | 1982-07-02 | 1982-07-02 | Filtrationsmembran samt sett att framstella membranet |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0098392A2 true EP0098392A2 (de) | 1984-01-18 |
EP0098392A3 EP0098392A3 (en) | 1984-03-07 |
EP0098392B1 EP0098392B1 (de) | 1987-12-09 |
Family
ID=20347268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83105534A Expired EP0098392B1 (de) | 1982-07-02 | 1983-06-06 | Membran und Verfahren zu ihrer Herstellung |
Country Status (11)
Country | Link |
---|---|
US (1) | US4722795A (de) |
EP (1) | EP0098392B1 (de) |
JP (1) | JPS5922605A (de) |
AT (1) | ATE31248T1 (de) |
AU (1) | AU561617B2 (de) |
BR (1) | BR8303493A (de) |
CA (1) | CA1226708A (de) |
DE (1) | DE3374840D1 (de) |
DK (1) | DK301483A (de) |
IE (1) | IE55038B1 (de) |
SE (1) | SE8204103L (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0479187A1 (de) * | 1990-10-05 | 1992-04-08 | Pall Corporation | Filter zur Filtration von Flüssigkeit |
EP0579749A1 (de) * | 1991-04-12 | 1994-01-26 | Minntech Corp | Magneto-hydrodynamisches fluidum behandlungssystem. |
US5334315A (en) * | 1992-01-17 | 1994-08-02 | Pall Corporation | Priming system |
WO2000002603A2 (en) * | 1998-07-10 | 2000-01-20 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
CN1076630C (zh) * | 1997-12-17 | 2001-12-26 | 四川联合大学 | 聚醚砜中空纤维膜及其制造方法和用途 |
US6499272B2 (en) | 1997-11-07 | 2002-12-31 | Huntsman Kcl Corporation | Method for placing a product in a flexible recloseable container |
WO2003009885A2 (en) * | 2001-07-25 | 2003-02-06 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
US6787040B2 (en) | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
US7291122B2 (en) | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867934A (en) * | 1987-12-23 | 1989-09-19 | Cuno, Inc. | Production of hollow nylon fibers |
US5006247A (en) * | 1989-08-15 | 1991-04-09 | Minnesota Mining And Manufacturing Company | Asymmetric porous polyamide membranes |
US5762798A (en) * | 1991-04-12 | 1998-06-09 | Minntech Corporation | Hollow fiber membranes and method of manufacture |
USRE36914E (en) * | 1992-10-07 | 2000-10-17 | Minntech Corp | Dialysate filter including an asymmetric microporous, hollow fiber membrane incorporating a polyimide |
US5318738A (en) * | 1993-04-13 | 1994-06-07 | E. I. Du Pont De Nemours And Company | Process of making hollow polyamide filaments |
CA2745612A1 (en) * | 2008-12-04 | 2010-06-10 | The University Of Akron | Polymer composition and dialysis membrane formed from the polymer composition |
EP2558088A4 (de) * | 2010-04-14 | 2014-01-15 | Univ Akron | Polymerzusammensetzung mit einer fotochemikalie und aus der polymerzusammensetzung hergestellte dialysemembran |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2236226B2 (de) | 1972-07-24 | 1974-07-04 | Forschungsinstitut Berghof Gmbh, 7400 Tuebingen | Verfahren zur Herstellung von semipermeablen asymmetrischen Kapillarmembranen |
US4181694A (en) | 1972-04-28 | 1980-01-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for producing hollow fibers of acrylonitrile polymers for ultrafilter |
US4229291A (en) | 1977-11-21 | 1980-10-21 | Hoechst Aktiengesellschaft | Permselective membrane and use |
EP0046816A1 (de) | 1980-09-01 | 1982-03-10 | Gambro, Inc. | Hämofiltrationsmembran aus Polycarbonat und eine derartige Membran verwendendes Hämofiltrationsverfahren |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5628564B2 (de) * | 1974-04-16 | 1981-07-02 | ||
JPS546916A (en) * | 1977-06-20 | 1979-01-19 | Asahi Chem Ind Co Ltd | Hollow cellulose fibers and their production |
JPS5416378A (en) * | 1977-07-08 | 1979-02-06 | Asahi Chem Ind Co Ltd | Polysulfone semipermeable membrane |
JPS5596162A (en) * | 1979-01-18 | 1980-07-22 | Asahi Medical Co | Polycarbonate hollow fiber dialysis film and its preparation |
JPS56152704A (en) * | 1980-04-25 | 1981-11-26 | Kanegafuchi Chem Ind Co Ltd | Hollow fiber membrane and its manufacture |
JPS5750508A (en) * | 1980-09-11 | 1982-03-25 | Mitsubishi Rayon Co Ltd | Permselective membrane and its production |
-
1982
- 1982-07-02 SE SE8204103A patent/SE8204103L/ unknown
-
1983
- 1983-06-06 EP EP83105534A patent/EP0098392B1/de not_active Expired
- 1983-06-06 AT AT83105534T patent/ATE31248T1/de not_active IP Right Cessation
- 1983-06-06 DE DE8383105534T patent/DE3374840D1/de not_active Expired
- 1983-06-20 IE IE1451/83A patent/IE55038B1/en unknown
- 1983-06-30 BR BR8303493A patent/BR8303493A/pt unknown
- 1983-06-30 CA CA000431628A patent/CA1226708A/en not_active Expired
- 1983-06-30 DK DK301483A patent/DK301483A/da not_active Application Discontinuation
- 1983-07-01 JP JP58120133A patent/JPS5922605A/ja active Granted
- 1983-07-01 AU AU16508/83A patent/AU561617B2/en not_active Ceased
-
1985
- 1985-09-30 US US06/782,597 patent/US4722795A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181694A (en) | 1972-04-28 | 1980-01-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for producing hollow fibers of acrylonitrile polymers for ultrafilter |
DE2236226B2 (de) | 1972-07-24 | 1974-07-04 | Forschungsinstitut Berghof Gmbh, 7400 Tuebingen | Verfahren zur Herstellung von semipermeablen asymmetrischen Kapillarmembranen |
US4229291A (en) | 1977-11-21 | 1980-10-21 | Hoechst Aktiengesellschaft | Permselective membrane and use |
EP0046816A1 (de) | 1980-09-01 | 1982-03-10 | Gambro, Inc. | Hämofiltrationsmembran aus Polycarbonat und eine derartige Membran verwendendes Hämofiltrationsverfahren |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0479187A1 (de) * | 1990-10-05 | 1992-04-08 | Pall Corporation | Filter zur Filtration von Flüssigkeit |
EP0478842A1 (de) * | 1990-10-05 | 1992-04-08 | PALL BIOMEDIZIN GmbH | Filter zur Filtration menschlicher Cerebronspinalflüssigkeit |
WO1992005864A1 (en) * | 1990-10-05 | 1992-04-16 | Pall Corporation | Filter for liquor filtration |
AU646501B2 (en) * | 1990-10-05 | 1994-02-24 | Pall Corporation | Filter for liquor filtration |
US5462667A (en) * | 1990-10-05 | 1995-10-31 | Pall Corporation | Filter for liquor filtration |
EP0579749A1 (de) * | 1991-04-12 | 1994-01-26 | Minntech Corp | Magneto-hydrodynamisches fluidum behandlungssystem. |
EP0579749A4 (de) * | 1991-04-12 | 1994-04-06 | Minntech Corp | |
US5334315A (en) * | 1992-01-17 | 1994-08-02 | Pall Corporation | Priming system |
US6499272B2 (en) | 1997-11-07 | 2002-12-31 | Huntsman Kcl Corporation | Method for placing a product in a flexible recloseable container |
CN1076630C (zh) * | 1997-12-17 | 2001-12-26 | 四川联合大学 | 聚醚砜中空纤维膜及其制造方法和用途 |
US6287516B1 (en) | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
WO2000002603A3 (en) * | 1998-07-10 | 2000-02-17 | Bioscience Research Associates | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
WO2000002603A2 (en) * | 1998-07-10 | 2000-01-20 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
US6730266B2 (en) | 1998-07-10 | 2004-05-04 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
US7291122B2 (en) | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
US7758533B2 (en) | 2000-03-24 | 2010-07-20 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices for treatment of chronic and acute diseases |
US6787040B2 (en) | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
US7520992B2 (en) | 2000-05-16 | 2009-04-21 | Imunocept, L.L.C. | Method and system for colloid exchange therapy |
US7524420B2 (en) | 2000-05-16 | 2009-04-28 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
WO2003009885A2 (en) * | 2001-07-25 | 2003-02-06 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
WO2003009885A3 (en) * | 2001-07-25 | 2003-07-03 | Immunocept L L C | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
Also Published As
Publication number | Publication date |
---|---|
BR8303493A (pt) | 1984-02-07 |
SE8204103D0 (sv) | 1982-07-02 |
DK301483A (da) | 1984-01-03 |
SE8204103L (sv) | 1984-01-03 |
JPH0453573B2 (de) | 1992-08-27 |
EP0098392A3 (en) | 1984-03-07 |
US4722795A (en) | 1988-02-02 |
CA1226708A (en) | 1987-09-15 |
ATE31248T1 (de) | 1987-12-15 |
IE55038B1 (en) | 1990-05-09 |
EP0098392B1 (de) | 1987-12-09 |
AU1650883A (en) | 1984-01-05 |
DE3374840D1 (en) | 1988-01-21 |
JPS5922605A (ja) | 1984-02-04 |
DK301483D0 (da) | 1983-06-30 |
AU561617B2 (en) | 1987-05-14 |
IE831451L (en) | 1984-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0098392A2 (de) | Membran und Verfahren zu ihrer Herstellung | |
US4439322A (en) | Polymethyl methacrylate membrane | |
US4286015A (en) | Polyaryl ether sulfone semipermeable membrane and process for producing same | |
JP2916446B2 (ja) | 非対称微孔性中空繊維の製造方法 | |
DE3875203T3 (de) | Verfahren zur Herstellung einer permselektiven, asymmetrischen Membrane, verwendbar in der Hämodialyse und die so hergestellten Membrane. | |
DE2829630C3 (de) | Semipermeable Membran und Verfahren zu ihrer Herstellung | |
CN100457242C (zh) | 改良的除去中分子的透析膜 | |
EP0193725B1 (de) | Verfahren zum Spinnen von Hohlfasermembranen | |
WO2005082501A1 (de) | Integral asymmetrische membran, verfahren zu ihrer herstellung und ihre verwendung | |
US5082565A (en) | Semipermeable membrane made from polyether ketones | |
JPH10230148A (ja) | 半透膜 | |
EP0044958B1 (de) | Plasmaphoresemembran und Verfahren zu ihrer Herstellung | |
JPS6238205A (ja) | 分離用半透膜 | |
JP7305621B2 (ja) | 微多孔膜およびその作製方法 | |
DE69308764T2 (de) | Blutverträgliche Materialien | |
EP0092587B1 (de) | Ultrafiltrationsmembran aus polymethylmethacrylathohlfaser sowie deren herstellungsverfahren | |
EP0824960A1 (de) | Hohlfasermembran aus polysulfon-polymer und verfahren zu ihrer herstellung | |
JP4352709B2 (ja) | ポリスルホン系半透膜およびそれを用いた人工腎臓 | |
JP2688564B2 (ja) | 酢酸セルロース中空糸分離膜 | |
JP3770145B2 (ja) | 半透膜の製造方法およびその半透膜を用いた透析器 | |
JP2000210544A (ja) | 半透膜の製造方法 | |
JP3464000B1 (ja) | 高性能中空糸状精密濾過膜の製造方法 | |
JPS5922559A (ja) | 血漿搬出法用の微孔質の中空繊維膜およびその製造方法 | |
JPS6045358A (ja) | 血漿分離膜及びその製造方法 | |
JPS6128409A (ja) | 芳香族ポリスルホン系分離膜の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL |
|
17P | Request for examination filed |
Effective date: 19840824 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL |
|
REF | Corresponds to: |
Ref document number: 31248 Country of ref document: AT Date of ref document: 19871215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3374840 Country of ref document: DE Date of ref document: 19880121 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19880630 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
26 | Opposition filed |
Opponent name: FRESENIUS AG Effective date: 19880908 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: FRESENIUS AG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19890606 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19890627 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19900101 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19900630 Ref country code: CH Effective date: 19900630 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: GAMBRO LUNDIA AB Owner name: GAMBRO DIALYSATOREN GMBH & CO. KG |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
ITTA | It: last paid annual fee | ||
27O | Opposition rejected |
Effective date: 19910308 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19940517 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19940525 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19940704 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19940726 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19950606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19950630 |
|
BERE | Be: lapsed |
Owner name: GAMBRO LUNDIA A.B. Effective date: 19950630 Owner name: GAMBRO DIALYSATOREN G.M.B.H & CO. K.G. Effective date: 19950630 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19950606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19960229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19960301 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |